GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (STU:A71) » Definitions » Cyclically Adjusted Revenue per Share

Ascendis Pharma A/S (STU:A71) Cyclically Adjusted Revenue per Share : €0.97 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Ascendis Pharma A/S Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ascendis Pharma A/S's adjusted revenue per share for the three months ended in Mar. 2024 was €1.686. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.97 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Ascendis Pharma A/S's average Cyclically Adjusted Revenue Growth Rate was 73.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-06-10), Ascendis Pharma A/S's current stock price is €125.00. Ascendis Pharma A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.97. Ascendis Pharma A/S's Cyclically Adjusted PS Ratio of today is 128.87.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ascendis Pharma A/S was 170.19. The lowest was 111.05. And the median was 135.80.


Ascendis Pharma A/S Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Ascendis Pharma A/S's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Cyclically Adjusted Revenue per Share Chart

Ascendis Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.86

Ascendis Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.62 0.73 0.86 0.97

Competitive Comparison of Ascendis Pharma A/S's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Ascendis Pharma A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma A/S's Cyclically Adjusted PS Ratio falls into.



Ascendis Pharma A/S Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ascendis Pharma A/S's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.686/118.4000*118.4000
=1.686

Current CPI (Mar. 2024) = 118.4000.

Ascendis Pharma A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.362 99.700 0.430
201409 0.192 99.700 0.228
201412 0.167 99.400 0.199
201503 0.085 100.200 0.100
201506 0.081 100.300 0.096
201509 0.086 100.200 0.102
201512 0.079 99.800 0.094
201603 0.050 100.200 0.059
201606 0.045 100.600 0.053
201609 0.046 100.200 0.054
201612 0.034 100.300 0.040
201703 0.011 101.200 0.013
201706 0.014 101.200 0.016
201709 0.013 101.800 0.015
201712 0.008 101.300 0.009
201803 0.001 101.700 0.001
201806 0.000 102.300 0.000
201809 0.000 102.400 0.000
201812 0.250 102.100 0.290
201903 0.125 102.900 0.144
201906 0.068 102.900 0.078
201909 0.047 102.900 0.054
201912 0.052 102.900 0.060
202003 0.046 103.300 0.053
202006 0.030 103.200 0.034
202009 0.052 103.500 0.059
202012 0.010 103.400 0.011
202103 0.014 104.300 0.016
202106 0.019 105.000 0.021
202109 0.020 105.800 0.022
202112 0.086 106.600 0.096
202203 0.120 109.900 0.129
202206 0.110 113.600 0.115
202209 0.274 116.400 0.279
202212 0.409 115.900 0.418
202303 0.599 117.300 0.605
202306 0.843 116.400 0.857
202309 0.854 117.400 0.861
202312 2.434 116.700 2.469
202403 1.686 118.400 1.686

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Ascendis Pharma A/S  (STU:A71) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ascendis Pharma A/S's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=125.00/0.97
=128.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ascendis Pharma A/S was 170.19. The lowest was 111.05. And the median was 135.80.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ascendis Pharma A/S Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma A/S (STU:A71) Business Description

Industry
Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S (STU:A71) Headlines

No Headlines